Categories: Technology

Aptean Unveils Aptean Intelligence as a Service, Delivering IndustryReady AI Agents That Drive Real Operational Results

ALPHARETTA, Ga., Feb. 09, 2026 (GLOBE NEWSWIRE) — As manufacturers and distributors move beyond AI experimentation, Aptean, a global leader in AI-powered, industry-specific enterprise software, is introducing Aptean Intelligence as a Service. This new service is designed to help businesses turn AI ambitions into operational outcomes. By delivering custom, industry-ready AI agents that integrate directly into day-to-day workflows, it removes the complexity, risk, and uncertainty that often stall AI initiatives.

Built on AppCentral 2.0, Aptean’s vertically focused AI platform, Aptean Intelligence as a Service gives businesses a clear, actionable roadmap – from identifying high‑value opportunities to deploying agents that deliver measurable results. It removes the technical burden, identifies where AI will create the greatest value, and empowers teams to eliminate bottlenecks, reduce downtime, and improve decision‑making with safe, governed, industry‑trained AI agents.

A White‑Glove Partnership for Real AI Adoption
Unlike generic AI tools that leave businesses to figure out AI implementation alone, Aptean Intelligence as a Service is delivered as a true white-glove partnership. Aptean’s experts work side-by-side with customers to identify high-impact operational bottlenecks. They design purpose-built agents and manage the full lifecycle, from deployment to ongoing optimization.

Key Stages Include:

Strategic Discovery: Identifying high-value use cases aligned with each business’s goals, processes, and operational constraints.

Custom Agent Deployment: Designing AI agents that act as operational teammates, for example, Customer Service Agents that automate order entry or Maintenance Agents that predict equipment failure before it disrupts production.

End-to-End Management: Aptean oversees design, deployment, monitoring and continuous improvement to ensure agents deliver sustained value over time.

Executive Perspective – Sean Nappo, EVP Americas, Aptean

“As AI reshapes industries, many organizations find themselves stuck in the experimentation phase, unsure where to start or how to scale,” said Sean Nappo, Executive Vice President, Americas at Aptean. “Aptean Intelligence as a Service gives them a practical, guided path forward. We don’t hand over abstract tools; we build custom agents that work alongside their employees to deliver operational impact. With our partnership approach, Aptean handles the complexity so businesses can adopt AI quickly, confidently, and cost-effectively.”

Customer Success
Early adopters of Aptean Intelligence as a Service, powered by AppCentral 2.0, are already seeing meaningful improvements in efficiency, accuracy, and throughput. These customers run mission‑critical operations, and the early results confirm that industry‑trained AI agents can deliver measurable impact in real‑world environments.

Customer Spotlight: Crew2 Accelerates AI Adoption with Aptean Intelligence as a Service

Erik Larson, Senior Vice President of Systems and Operations, Crew2

“Over the past decade, Crew2 built a strong operational foundation on Aptean’s solutions. Our move to the cloud was a pivotal step, allowing us to apply AI in a practical, responsible way. Through Aptean’s AIaaS (Aptean Intelligence as a Service) program, we are deploying customized AI agents, starting with lead management and expanding into self-scheduling that will help our teams make faster decisions, gain better visibility, and execute consistently at scale. This marks an exciting new phase in how we run our business.”

Toufayan Bakeries Strengthens Traceability with AI Agents

Robert Piergiovanni, ERP Implementation Manager, Toufayan Bakeries

“We started testing with our Aptean AI traceability agent. Pretty powerful. What used to take our 8-person traceability team 4 hours can now be done with a single person in under an hour. Time will probably be reduced even further once testing is done and the process is solidified.”

To learn more about how Aptean Intelligence as a Service can transform your business, contact ready@aptean.com or visit https://www.aptean.com/en-IE/appcentral.

About Aptean:   

Aptean is a global provider of industry-specific software that helps manufacturers and distributors effectively run and grow their businesses. Aptean’s solutions and services help businesses of all sizes to be Ready for What’s Next, Now®. Aptean is headquartered in Alpharetta, Georgia and has offices in North America, Europe and Asia Pacific. To learn more about Aptean and the markets we serve, visit www.aptean.com.

For media queries: geraldine.oneill@aptean.com 

GlobeNews Wire

Recent Posts

FemiCore (Official Website & Authenticity Notice 2026) Counterfeit Risks and What Consumers Should Know

New York City, NY, June 13, 2026 (GLOBE NEWSWIRE) -- The women's health supplement market…

15 hours ago

Hitch Open Ping-Pong Embodied (HOPE) AI Challenge Joins the 2026 World Humanoid Robot Games, Seeding Advanced Physical AI Against Human Performance

BEIJING, June 13, 2026 (GLOBE NEWSWIRE) -- The 2026 Hitch Open Ping-Pong Embodied AI Challenge…

15 hours ago

Crypto News Today: AlphaPepe Unveils AlphaSwap Early Access as Bitcoin Price Prediction Eyes $250,000

MONACO, June 12, 2026 (GLOBE NEWSWIRE) -- Crypto news today is turning toward AlphaPepe after…

15 hours ago

Hexaware Expands Presence in Gujarat with New Delivery Center at GIFT City

MUMBAI, India, LONDON and ISELIN, N.J., June 13, 2026 /PRNewswire/ -- Hexaware Technologies [NSE: HEXT], a…

17 hours ago

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI…

18 hours ago

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

June 13, 2026 07:30 ET  | Source: Intellia Therapeutics, Inc. Data from HAELO Phase 3…

18 hours ago